March 2025 Penny Stocks To Consider For Growth

As the U.S. stock market grapples with economic uncertainties and fluctuating indices, investors are increasingly exploring diverse opportunities for growth. Penny stocks, often associated with smaller or newer companies, continue to capture interest due to their potential for significant returns at lower price points. Despite being considered a somewhat outdated term, these stocks can offer substantial growth prospects when backed by solid financials and strong fundamentals.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$118.58M	★★★★★★
Safe Bulkers (NYSE:SB)	$3.74	$393.82M	★★★★☆☆
BAB (OTCPK:BABB)	$0.8526	$6.19M	★★★★★☆
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.50	$75.83M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.45	$47.85M	★★★★★★
PHX Minerals (NYSE:PHX)	$4.04	$151.42M	★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)	$1.30	$23.06M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8126	$73.08M	★★★★★☆
TETRA Technologies (NYSE:TTI)	$3.79	$501.77M	★★★★☆☆

Click here to see the full list of 748 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Alpha Tau Medical (NasdaqCM:DRTS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on the research, development, and commercialization of Alpha DaRT for treating solid cancer in Israel and the United States, with a market cap of $211.71 million.

Operations: Alpha Tau Medical Ltd. currently does not report any revenue segments as it is focused on the clinical-stage development and commercialization of its cancer treatment technology.

Market Cap: $211.71M

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, remains pre-revenue with a market cap of US$211.71 million. Recent FDA approval to expand its clinical trial for Alpha DaRT in pancreatic cancer patients highlights potential growth avenues, though the company is currently unprofitable and has seen increased losses over the past five years. Despite this, it maintains a stable financial position with short-term assets exceeding liabilities and sufficient cash runway for over two years if current cash flow trends persist. The management team is experienced, and shareholders have not faced significant dilution recently.

• Click here and access our complete financial health analysis report to understand the dynamics of Alpha Tau Medical.
• Assess Alpha Tau Medical's future earnings estimates with our detailed growth reports.

Wrap Technologies (NasdaqCM:WRAP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Wrap Technologies, Inc. is a public safety technology and services company that develops policing solutions for law enforcement and security personnel globally, with a market cap of $100.48 million.

Operations: The company generates revenue primarily from its Aerospace & Defense segment, amounting to $4.23 million.

Market Cap: $100.48M

Wrap Technologies, Inc., with a market cap of US$100.48 million, recently executed a private placement raising approximately US$5.79 million to bolster its cash position amidst ongoing losses and volatility. The company remains unprofitable, with earnings declining by 16.1% annually over the past five years, but its short-term assets exceed liabilities by US$1.5 million, providing some financial stability. Despite having an inexperienced board and management team averaging less than two years in tenure, Wrap is debt-free and actively expanding its product offerings like the MSR Connected Ecosystem to enhance public safety solutions in Virginia and beyond.

• Get an in-depth perspective on Wrap Technologies' performance by reading our balance sheet health report here.
• Gain insights into Wrap Technologies' historical outcomes by reviewing our past performance report.

Sight Sciences (NasdaqGS:SGHT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing surgical and nonsurgical technologies for treating eye diseases, with a market cap of approximately $134.50 million.

Operations: Sight Sciences generates revenue primarily from its Surgical Glaucoma segment, which accounts for $74.28 million, and the Dry Eye segment, contributing $5.26 million.

Market Cap: $134.5M

Sight Sciences, Inc., with a market cap of US$134.50 million, focuses on ophthalmic medical devices and faces challenges as it remains unprofitable with increasing losses over the past five years. Despite a negative return on equity and significant insider selling recently, its short-term assets of US$140.5 million comfortably cover both short-term and long-term liabilities. The company has more cash than debt, providing some financial cushion alongside a cash runway exceeding three years based on current free cash flow trends. Recent presentations at prominent conferences highlight ongoing efforts to strengthen its position in the medical device sector.

• Click here to discover the nuances of Sight Sciences with our detailed analytical financial health report.
• Gain insights into Sight Sciences' outlook and expected performance with our report on the company's earnings estimates.

Make It Happen

• Jump into our full catalog of 748 US Penny Stocks here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com